📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 16:23
538 analysed today
FollowTelegram
538
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Q1 PAT Drops 21% YoY to ₹1.11 Cr; Auditor Flags Regulatory Risk on Production Limits
Everest Organics reported a weak Q1 FY27 with total income declining 9.2% YoY to ₹48.85 Cr. Net Profit (PAT) fell 21.3% YoY to ₹1.11 Cr, and more sharply by 57.8% on a sequential basis compared to Q4 FY26. A critical concern is the statutory auditor's qualification, which states the company is operating at production levels exceeding those approved by the Telangana State Pollution Control Board (TSPCB). While the company has applied for the necessary Consent for Operation (CFO) for its expansion, the current lack of approval poses a potential risk of a closure order.
Confidence: HIGH
What changedThe company's financial performance has deteriorated both YoY and QoQ, and the statutory auditor has formally flagged a significant regulatory non-compliance risk regarding production capacities.
Why it mattersThe regulatory risk is a 'going concern' threat that could lead to a production halt. Financially, the company is struggling to maintain margins in a mature API segment while facing high raw material dependency on China.
Total Income (Q1 FY27): ₹48.85 CrNet Profit (Q1 FY27): ₹1.11 CrYoY PAT Growth: -21.3%QoQ PAT Growth: -57.8%Export Share of Sales: 22.2%Q1 Revenue vs TTM Revenue: 24.9%
📅 Short termNegative sentiment is expected due to the earnings decline and the serious nature of the auditor's qualification regarding unauthorized production levels.
📈 Long termLong-term growth is contingent on regularizing the 3X capacity expansion and successfully diversifying into the Phytochemical-immune segment to reduce reliance on the mature Prazole segment.
⚠ Risk flags
- Regulatory non-compliance (TSPCB production limits)
- High raw material dependency on China (70-80%)
- Limited pricing power in mature API segments
Key Highlights
Total Income for Q1 FY27 stood at ₹48.85 Cr, down from ₹53.81 Cr in Q1 FY26.
Net Profit (PAT) decreased to ₹1.11 Cr, representing a 21.3% decline YoY and a 57.8% decline QoQ.
Export turnover reached ₹10.78 Cr, contributing approximately 22.2% of the total sales turnover.
Auditor qualified the report noting the company is operating at 'substantially enhanced' production levels without necessary CFO approvals.
Earnings Per Share (EPS) for the quarter fell to ₹1.15 from ₹1.45 in the year-ago period.
👀 What to Watch
Investors should closely monitor the status of the 'Consent for Operation' (CFO) application with the TSPCB, as any adverse regulatory action or closure order would materially halt production.
Rs 4 Crore Allotment: Everest Organics Converts 2.63 Lakh Warrants for Promoter
Everest Organics Limited has approved the allotment of 2,63,157 equity shares to its Managing Director and Promoter, Dr. Sri Kakarlapudi Sirisha. The shares were issued at a price of Rs. 152 per share (including a premium of Rs. 142) upon the conversion of warrants originally issued in January 2025. The company received the final 75% payment of Rs. 2,99,99,898 to complete the total transaction value of approximately Rs. 4 crore. These shares are subject to a mandatory 18-month lock-in period from the date of trading approval.
Confidence: HIGH
What changedThe company has converted 2,63,157 warrants into equity shares, resulting in a capital infusion of approximately Rs. 4 crore and an increase in the promoter's equity holding.
Why it mattersPromoter warrant conversion at a fixed price (Rs. 152) signals long-term commitment and provides the company with additional working capital or debt reduction funds.
Shares Allotted: 2,63,157Issue Price per Share: Rs. 152Total Amount Received: Rs. 3,99,99,864Balance 75% Payment: Rs. 2,99,99,898Lock-in Period: 18 months
📅 Short termThe news is likely to be viewed neutrally to slightly positively by the market as it confirms the promoter's intent to follow through on capital warrants issued in 2025.
📈 Long termThe increase in promoter skin-in-the-game is a positive structural signal, though the absolute quantum of Rs. 4 crore is relatively small for a listed entity.
Key Highlights
Allotment of 2,63,157 fully paid-up equity shares of Rs. 10 face value each
Total transaction value aggregates to Rs. 3,99,99,864 at an issue price of Rs. 152 per share
Receipt of balance 75% consideration amounting to Rs. 2,99,99,898 from the Promoter
Warrants were originally allotted on January 13, 2025, following shareholder approval on January 08, 2025
Mandatory lock-in period of 18 months for the newly allotted promoter shares
👀 What to Watch
Investors should monitor the upcoming shareholding pattern disclosure to quantify the exact percentage increase in promoter stake and track the utilization of the Rs. 4 crore proceeds in future quarterly results.
